| [1] | Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017; 124(10): 1501-1512. doi: 10.1111/1471-0528.14640. |
| [2] | Giuliani E, As-Sanie S, Marsh EE. Epidemiology and management of uterine fibroids. Int J Gynaecol Obstet. 2020; 149(1): 3-9. doi: 10.1002/ijgo.13102. |
| [3] | Pérez-Roncero GR, López-Baena MT, Ornat L, Cuerva MJ, Garcia-Casarrubios P, Chedraui P, et al. Uterine fibroids and preterm birth risk: A systematic review and meta-analysis. J Obstet Gynaecol Res. 2020 Sep; 46(9): 1711-1727. doi: 10.1111/jog.14343. |
| [4] | Coutinho LM, Assis WA, Spagnuolo-Souza A, Reis FM. Uterine Fibroids and Pregnancy: How Do They Affect Each Other? Reprod Sci. 2022; 29(8): 2145-2151. doi: 10.1007/s43032-021-00656-6. |
| [5] | Pritts EA. Uterine Leiomyomas and Reproduction. Obstet Gynecol. 2025; 145(1): 39-45. doi: 10.1097/AOG.0000000000005748. |
| [6] | Marsh EE, Al-Hendy A, Kappus D, Galitsky A, Stewart EA, Kerolous M. Burden, Prevalence, and Treatment of Uterine Fibroids: A Survey of U.S. Women. J Womens Health (Larchmt). 2018; 27(11): 1359-1367. doi: 10.1089/jwh.2018.7076. |
| [7] | Yang Q, Ciebiera M, Bariani MV, Ali M, Elkafas H, Boyer TG, et al. Comprehensive Review of Uterine Fibroids: Developmental Origin, Pathogenesis, and Treatment. Endocr Rev. 2022; 43(4): 678-719. doi: 10.1210/endrev/bnab039. |
| [8] | Boos D, Chuang TD, Abbasi A, Luzzi A, Khorram O. The immune landscape of uterine fibroids as determined by mass cytometry. F S Sci. 2024; 5(3): 272-282. doi: 10.1016/j.xfss.2024.06.004. |
| [9] | Ishikawa H, Kobayashi T, Kaneko M, Saito Y, Shozu M, Koga K. RISING STARS: Role of MED12 mutation in the pathogenesis of uterine fibroids. J Mol Endocrinol. 2023; 71(4): e230039. doi: 10.1530/JME-23-0039. |
| [10] | Liu J, Xiao Q, Xiao J, Niu C, Li Y, Zhang X, et al. Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities. Signal Transduct Target Ther. 2022; 7(1): 3. doi: 10.1038/s41392-021-00762-6. |
| [11] | Mittal P, Shin YH, Yatsenko SA, Castro CA, Surti U, Rajkovic A. Med12 gain-of-function mutation causes leiomyomas and genomic instability. J Clin Invest. 2015 Aug 3; 125(8): 3280-4. doi: 10.1172/JCI81534. |
| [12] | Ono M, Yin P, Navarro A, Moravek MB, Coon JS 5th, Druschitz SA, et al. Paracrine activation of WNT/β-catenin pathway in uterine leiomyoma stem cells promotes tumor growth. Proc Natl Acad Sci USA. 2013; 110(42): 17053-8. doi: 10.1073/pnas.1313650110. |
| [13] | Goad J, Rudolph J, Zandigohar M, Tae M, Dai Y, Wei JJ, et al. Single-cell sequencing reveals novel cellular heterogeneity in uterine leiomyomas. Hum Reprod. 2022; 37(10): 2334-2349. doi: 10.1093/humrep/deac183 |
| [14] | Orciani M, Caffarini M, Biagini A, Lucarini G, Delli Carpini G, Berretta A, et al. Chronic Inflammation May Enhance Leiomyoma Development by the Involvement of Progenitor Cells. Stem Cells Int. 2018; 2018: 1716246. doi: 10.1155/2018/1716246. |
| [15] | Moretti L, Stalfort J, Barker TH, Abebayehu D. The interplay of fibroblasts, the extracellular matrix, and inflammation in scar formation. J Biol Chem. 2022; 298(2): 101530. doi: 10.1016/j.jbc.2021.101530. |
| [16] | Saad EE, Michel R, Borahay MA. Immunosuppressive tumor microenvironment and uterine fibroids: Role in collagen synthesis. Cytokine Growth Factor Rev. 2024; 75: 93-100. doi: 10.1016/j.cytogfr.2023.10.002. |
| [17] | Islam MS, Ciavattini A, Petraglia F, Castellucci M, Ciarmela P. Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics. Hum Reprod Update. 2018; 24(1): 59-85. doi: 10.1093/humupd/dmx032. |
| [18] | Giuliani A, Greco S, Pacilè S, Zannotti A, Delli Carpini G, Tromba G, et al. Advanced 3D Imaging of Uterine Leiomyoma's Morphology by Propagation-based Phase-Contrast Microtomography. Sci Rep. 2019; 9(1): 10580. doi: 10.1038/s41598-019-47048-0. |
| [19] | Governini L, Marrocco C, Semplici B, Pavone V, Belmonte G, Luisi S, et al. Extracellular matrix remodeling and inflammatory pathway in human endometrium: insights from uterine leiomyomas. Fertil Steril. 2021; 116(5): 1404-1414. doi: 10.1016/j.fertnstert.2021.06.023. |
| [20] | Protic O, Toti P, Islam MS, Occhini R, Giannubilo SR, Catherino WH, et al. Possible involvement of inflammatory/reparative processes in the development of uterine fibroids. Cell Tissue Res. 2016; 364(2): 415-27. doi: 10.1007/s00441-015-2324-3. |
| [21] | Liu ZQ, Lu MY, Sun RL, Yin ZN, Liu B, Wu YZ. Characteristics of Peripheral Immune Function in Reproductive Females with Uterine Leiomyoma. J Oncol. 2019; 2019: 5935640. doi: 10.1155/2019/5935640. |
| [22] | Wang Z, Du K, Jin N, Tang B, Zhang W. Macrophage in liver Fibrosis: Identities and mechanisms. Int Immunopharmacol. 2023; 120: 110357. doi: 10.1016/j.intimp.2023.110357. |
| [23] | Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014; 6: 13. doi: 10.12703/P6-13. |
| [24] | Oishi Y, Manabe I. Macrophages in inflammation, repair and regeneration. Int Immunol. 2018; 30(11): 511-528. doi: 10.1093/intimm/dxy054. |
| [25] | Wen JH, Li DY, Liang S, Yang C, Tang JX, Liu HF. Macrophage autophagy in macrophage polarization, chronic inflammation and organ fibrosis. Front Immunol. 2022; 13: 946832. doi: 10.3389/fimmu.2022.946832. |
| [26] | Zannotti A, Greco S, Pellegrino P, Giantomassi F, Delli Carpini G, Goteri G, et al. Macrophages and Immune Responses in Uterine Fibroids. Cells. 2021; 10(5): 982. doi: 10.3390/cells10050982. |
| [27] | Yu H, Lin L, Zhang Z, Zhang H, Hu H. Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct Target Ther. 2020; 5(1): 209. doi: 10.1038/s41392-020-00312-6. |
| [28] | Dhanani Z, Jimenez Ramirez N, Nguyen J, Rosenberg-Hasson Y, Naseri S, Lum D, et al. Differences in menstrual cytokine profiles of women with and without symptomatic uterine fibroids. F S Sci. 2023; 4(4): 339-340. doi: 10.1016/j.xfss.2023.09.006. |
| [29] | Ciebiera M, Włodarczyk M, Wrzosek M, Wojtyła C, Błażej M, Nowicka G, et al. TNF-α serum levels are elevated in women with clinically symptomatic uterine fibroids. Int J Immunopathol Pharmacol. 2018; 32: 2058738418779461. doi: 10.1177/2058738418779461. |
| [30] | Mahdi HS. Assessment pro-inflammatory factors and cytokines in uterine fibroid. JOGC Research. 2025; e721476. |
| [31] | Wang Y, Feng G, Wang J, Zhou Y, Liu Y, Shi Y, et al. Differential effects of tumor necrosis factor-α on matrix metalloproteinase-2 expression in human myometrial and uterine leiomyoma smooth muscle cells. Hum Reprod. 2015; 30(1): 61-70. doi: 10.1093/humrep/deu300. |
| [32] | Alsharidah M, Elsafadi M, Al Rugaie O, Mahmood A, Mohany KM, A Al-Regaiey K, et al. Mesenchymal stem cells treated with Interleukin-1 beta for mediation of an inflammatory response in human tissues. Cell Mol Biol (Noisy-le-grand). 2024; 70(10): 30-36. doi: 10.14715/cmb/2024.70.10.5. |
| [33] | Plewka A, Madej P, Plewka D, Kowalczyk A, Miskiewicz A, Wittek P, et al. Immunohistochemical localization of selected pro-inflammatory factors in uterine myomas and myometrium in women of various ages. Folia Histochemica Cytobiologica. 2013; 5173–83. doi: 10.5603/FHC.2013.0011 |
| [34] | de Mezer M, Dolata N, Markowska J, Krzyżaniak M, Naskręt-Grochowalska A, Żurawski J, et al. Immunohistochemical expression of IL-1β, IL-6, and NF-κβ in fibroids. Front Immunol. 2025; 16: 1571585. doi: 10.3389/fimmu.2025.1571585. |
| [35] | Konenkov VI, Koroleva EG, Orlov NB, Prokof’ev VF, Shevchenko AV, Novikov AM, et al. Blood serum levels of proinflammatory cytokines (IL-1β, IL-6, TNFα, IL-8, IL-12p70, and IFNγ) in patients with uterine myoma. Bull Exp Biol Med. 2018; 165: 698–701. doi: 10.1007/s10517-018-4245-0 |
| [36] | Ciebiera M, Włodarczyk M, Wrzosek M, Męczekalski B, Nowicka G, Łukaszuk K, et al. Role of Transforming Growth Factor β in Uterine Fibroid Biology. Int J Mol Sci. 2017; 18(11): 2435. doi: 10.3390/ijms18112435. |
| [37] | Vallée A, Lecarpentier Y. TGF-β in fibrosis by acting as a conductor for contractile properties of myofibroblasts. Cell Biosci. 2019; 9: 98. doi: 10.1186/s13578-019-0362-3. |
| [38] | Kamalipooya S, Zarezadeh R, Latifi Z, Nouri M, Fattahi A, Salemi Z. Serum transforming growth factor β and leucine-rich α-2-glycoprotein 1 as potential biomarkers for diagnosis of uterine leiomyomas. J Gynecol Obstet Hum Reprod. 2021; 50(3): 102037. doi: 10.1016/j.jogoh.2020.102037. |
| [39] | Lewis TD, Malik M, Britten J, Parikh T, Cox J, Catherino WH. Ulipristal acetate decreases active TGF-β3 and its canonical signaling in uterine leiomyoma via two novel mechanisms. Fertil Steril. 2019; 111(4): 806-815.e1. doi: 10.1016/j.fertnstert.2018.12.026. |
| [40] | Szydłowska I, Grabowska M, Nawrocka-Rutkowska J, Kram A, Piasecka M, Starczewski A. Markers of Inflammation and Vascular Parameters in Selective Progesterone Receptor Modulator (Ulipristal Acetate)-Treated Uterine Fibroids. J Clin Med. 2021; 10(16): 3721. doi: 10.3390/jcm10163721. |
| [41] | Ramadass V, Vaiyapuri T, Tergaonkar V. Small Molecule NF-κB Pathway Inhibitors in Clinic. Int J Mol Sci. 2020; 21(14): 5164. doi: 10.3390/ijms21145164. |
| [42] | Chuang TD, Ton N, Rysling S, Khorram O. In Vivo Effects of Bay 11-7082 on Fibroid Growth and Gene Expression: A Preclinical Study. Cells. 2024; 13(13): 1091. doi: 10.3390/cells13131091. |
| [43] | AlAshqar A, Patzkowsky K, Afrin S, Wild R, Taylor HS, Borahay MA. Cardiometabolic Risk Factors and Benign Gynecologic Disorders. Obstet Gynecol Surv. 2019; 74(11): 661-673. doi: 10.1097/OGX.0000000000000718. |
| [44] | Sánchez-Jiménez F, Pérez-Pérez A, de la Cruz-Merino L, Sánchez-Margalet V. Obesity and Breast Cancer: Role of Leptin. Front Oncol. 2019; 9: 596. doi: 10.3389/fonc.2019.00596. |
| [45] | Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer. 2015; 15(8): 484-98. doi: 10.1038/nrc3967. |
| [46] | Sun K, Xie Y, Zhao N, Li Z. A case-control study of the relationship between visceral fat and development of uterine fibroids. Exp Ther Med. 2019; 18(1): 404-410. doi: 10.3892/etm.2019.7575. |